Navigation Links
Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie
Date:9/5/2007

- In Patients With BPH, Clinical Benefit After Ozarelix Was Maintained For

Up To Six Months - Pivotal Trials Expected To Commence Before Year End Or Soon Thereafter

IRVINE, Calif., Sept. 5 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc., (Nasdaq: SPPI) today presented updated Phase 2 safety and efficacy data for ozarelix, the Company's drug candidate for the treatment of benign prostatic hypertrophy (BPH), at the 29th Congress of the Societe Internationale d'Urologie in Paris, France.

"The results of this Phase 2 study demonstrate that the effects of a single dosing regimen consisting of two injections on day one and fifteen are maintained for up to six months, which is superior to what is usually seen with currently approved drugs for BPH," said Rajesh C. Shrotriya, M.D., Chairman, President and Chief Executive Officer of Spectrum Pharmaceuticals. "A second 78-patient U.S. Phase 2b study, in which duration of follow-up is 9 months, completed enrollment in May. We look to the Phase 2b data to verify and expand on the experience from the Phase 2 study presented today. We continue to believe that ozarelix could help serve the large unmet medical need for more effective BPH treatments."

The efficacy and safety of ozarelix, a GnRH antagonist, given intramuscularly (IM) was assessed in men with moderate to severe Lower Urinary Tract Symptoms (LUTS) due to BPH in a randomized, double-blind, placebo- controlled, multi-center, Phase 2 dose-ranging study.

Eligible patients entered a 4-week, single blind, placebo run-in to establish baseline IPSS and urine-flow values. Patients (N=144) meeting the inclusion criteria were randomly allocated and received an IM injec
'/>"/>

SOURCE Spectrum Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
2. Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at Annual Meeting of American Urological Association
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013  TechAtlas Group has announced the release ... map for the Chronic Kidney Disease (CKD) market. ... with drugs and devices currently on the market ... (Logo:  http://photos.prnewswire.com/prnh/20130517/NE16011LOGO ) ... - renal denervation , diabetic nephropathy - ...
(Date:5/17/2013)... MIAMI LAKES, Fla. , May 17, 2013 ... products and delivery technology company that is developing new, patent-pending ... and minerals, announced today that it will hold a business ... on Wednesday, May 22 nd , 2013 at 4:30 PM ... Brian Tuffin will host the call and will ...
(Date:5/17/2013)... (EURONEXT: SAN and NYSE: SNY ) announced today ... examining the selective JAK2 inhibitor SAR302503 for myelofibrosis (MF), ... primary endpoint assessed the proportion of patients achieving >/=35% ... previous trials, the most common adverse events were anemia, ... at an upcoming medical congress. MF ...
Breaking Medicine Technology:TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
... Inc. (Nasdaq: STXS ) today announced that executive ... Conference on Tuesday, September 28, 2010 at 8:30 a.m. ET ... an overview of the Company,s business strategy and recent corporate ... invitation only. A live audio and slides webcast of Stereotaxis, ...
... BEDFORD, Mass., Sept. 23 Instrumentation Laboratory (IL), today announced ... on Wednesday, October 13, 2010 at the Grand Hyatt Nusa ... am to 12:00 pm, local time.  The forum will focus ... hemostasis.  All healthcare professionals, practicing in the Asia Pacific region ...
Cached Medicine Technology:Stereotaxis to Present at the JMP Securities Healthcare Conference 2Stereotaxis to Present at the JMP Securities Healthcare Conference 3Instrumentation Laboratory to Host 2nd Asia Pacific Hemostasis Forum 2Instrumentation Laboratory to Host 2nd Asia Pacific Hemostasis Forum 3Instrumentation Laboratory to Host 2nd Asia Pacific Hemostasis Forum 4
(Date:5/19/2013)... 19, 2013 The Fat Loss Code program ... secrets that help people get in shape, and gain ... shape. The program also is a natural fat loss system ... the author of this fat loss diet program claimed that ... can help people keep body fat off long-term. After Shawn ...
(Date:5/19/2013)... Agora Health Limited developed by Rachael Linkie is a new ... increase memory power naturally and effectively. The program also ... their entire health from the inside out. It also helps ... mind. In addition, the program helps people keep their memory ... claimed that this program can help people overcome a family ...
(Date:5/19/2013)... IL (PRWEB) May 19, 2013 Beginning Wednesday, ... River Valley Blood Center (RRVBC) will feature “Hot Dog Wednesdays" ... Belvidere. RRVBC will provide hot dogs and all the ... ice-cold slushies each day throughout the summer. “Donors are our ... maintain a stable and adequate blood supply. This is ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 HealthEconomics.Com ... access, is pleased to unveil a new and exciting ... that provides a powerful array of real-time communication tools ... the US and abroad. , HE-Xpo is powered by ... attendees the look and feel of being at a ...
(Date:5/19/2013)... The Da Vinci robot lawyers at ... the nation’s first trial involving a Da Vinci surgical ... Superior Court, was filed by the widow of a ... in a robot-assisted prostate removal, according to a report ... surgery lawsuit alleges those complication’s hastened his death. ...
Breaking Medicine News(10 mins):Health News:Weight Loss Secrets | How “The Fat Loss Code” Helps People Gain A Healthy Life And Get In Shape - Health Review 2Health News:How To Increase Memory Power | How “Agora Health Limited” Helps People Improve Their Memory Naturally And Effectively – Health Review 2Health News:Hot Dog Wednesdays and Ice Cold Slushies Return to Rock River Valley Blood Center for the Summer 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 3Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 2Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 3Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 4
... engineering students today took out a rally here to ... reservation to OBC in higher educational institutions. // ... Dental College and engineering colleges today took out a ... Engineering College and other important places of the city ...
... India, must face the challenges of reforming their health ... access to effective healthcare // , while protecting their ... new World Bank report said. ,The report warned ... sharply rising costs even while countries are scrambling to ...
... treatment would be provided to persons suffering from chronic ... cashew plantations in Kasaragod district, Health Minister P K ... programme here, she said the treatment would be made ... cards' by the government., ,A separate department for ...
... Techniques Act is to be enforced strictly in Kerala to ... today. // ,Addressing reporters here, she said there ... state, which was healthy at one time, had become unfavourable ... committee monitoring the implementation of the PNDT Act, said the ...
... Lester Crawford prevented two senior officials// from deciding the course ... a 'morning after' pill. ,These statements were contained ... Rights. Dr. Steven Galson, director of the FDA's Center for ... approving the action to sell Plan B as a OTC ...
... Punjab and Haryana were paralysed today as doctors of ... in the wake of a 'medical bandh' called by ... proposal. ,"All OPDs, including parallel ones run by ... institutions have been stopped", Association of Resident Doctors (ARD) ...
Cached Medicine News:
Conforms to the convexity of the lens providing easier access to anterior capsule. Reduces pontential of corneal touch. 23G x 5/8in (.60 x 16mm)...
... surgery and other types of refractive surgery. ... stromal bed. Flattened tip provides easy insertion ... flap edge. Multiple ports provide multi-directional irrigation. ... 9mm from end. Two .15mm ports 2mm ...
... product designed for LASIK surgery and ... to irrigate the corneal interface and/or ... insertion under the flap and helps ... provide multi-directional irrigation. 21G x 7/8in ...
Cannula tip is specially rounded, extra smooth for safe insertion through wound and manipulation in the anterior chamber. 27G x 7/8 in (.40 x 22mm)....
Medicine Products: